WHO recommends Merck's COVID pill for high-risk patients

A World Health Organization (WHO) panel on Wednesday backed the use of Merck & Co Inc's COVID-19 antiviral pill for high-risk patients. The expert panel conditionally recommended the pill, molnupiravir, for patients with non-severe disease who are at high risk of hospitalisation, such as the immunocompromised, the unvaccinated, older people and those with chronic diseases. The recommendation was based on new data from six clinical trials involving 4,796 patients.